Traumatic brain injury (TBI) constitutes a major health and socioeconomic problem throughout the world. Despite the signi cant advances in neuroradiology and cerebral monitoring it is still dif cult to measure the degree of primary brain injury and continuing secondary damage with Glasgow Coma Scale score or the initial computed tomography. Predicting prognosis of TBI patients in early stages has a vital importance and is dif cult in some instances. The present review shows that there has been an increasing interest in biochemical markers for traumatic brain injury during the last years. The potential correlation of markers with injury and outcome measures in severe head injury is promising.
Introduction
Traumatic brain injury (TBI) constitutes a major heal th and socioeconomic problem throughout the world. Globally, TBI is a leading cause of death and disability in children and young adults. It is the primary cause of death in 30%-50% of all injury-related deaths. [1] [2] [3] Despite the signi cant advances in cerebral monitoring, it is still di cult to measure the degree of primary brain injury and continuing secondary damage with Glasgow Coma Scale (GCS) score or the initial computed tomography (CT). Predicting prognosis of TBI patients in early stages has a vital importance and is di cult in some instances. [4] [5] [6] Attempts to predict clinical outcome or mortality using the admission GCS or CT-scan ndings have not been as reliable as we would like. Petzold et al. 7 found that the initial GCS of 3-8 predicted fatal outcome with a sensitivity of only 62%. is is partially due to the use of intubation and intravenous sedation, anesthetics and neuromuscular blockade in the early resuscitation e orts. 8 Consequently, increasing research is being devoted to the development of other tools to assess the severity of the initial brain injury, to identify patients at high risk for mortality and morbidity, and to predict outcome. ese challenges have created a need for biomarkers that re ect core elements of the disease process.
Biomarkers
Nowadays several specialties employ biomarker blood tests to diagnose, direct treatment, and prognosticate. e most common used biomarkers include troponin T/CK-Mb in cardiology, procalcitonin in sepsis, amylase and lipase in pancreatic disease. Regarding to a TBI biomarker this should show high speci city and sensitivity for brain, be released only a er irreversible destruction of brain tissue, have a rapid appearance in serum, show low age-and sex-related variability, and have reliable assays for immediate analysis. 9 ere are many structural markers of brain injury that have been examined in TBI. ese biomarkers reect damage from each of the major cell types in brain parenchyma (astrocytes, neurons and axons) have been studied. 9 ey may be released in response to oxidative stress, in ammation, cerebral blood ow dysregulation, excitotoxicity, apoptosis and cell death. 10 Although several potential biomarkers have been assessed in the past, for the purposes of this review, we will focus on the markers of structural brain injury that have received the most attention in recent clinical series. ese include S100B, neuron-speci c enolase (NSE), myelin basic protein (MBP), and glial brillary acid protein (GFAP).
S-100B
S-100B protein belongs to a multigenic family of low molecular weight (9-13 kD) calcium-binding S100 proteins that is most abundant in glial cells of the central nervous system, predominantly in astrocytes. 11 It is functionally involved in the regulation of cell morphology by interaction with elements of the cytoplasmatic cytoskeleton and is actively secreted from astroglia via an unknown mechanism. Its biological half-life is of 2h, not in uenced by hemolysis, and remains stable even if samples are not centrifuged and frozen immediately. Protein S100B can be detected in both cerebrospinal uid (CSF) and blood. Its concentration has been shown to increase in CSF and/or serum a er a number of cerebral diseases, including traumatic brain injury, cerebral infarction, subarachnoid hemorrhage and parenchymal infections. [12] [13] [14] [15] [16] [17] e samples can be removed from arterial lines, but some investigators have advocated the use of jugular venous lines to measure S100B in an attempt to avoid mixing in fractions of S100B that arise from others sites. 18 Some investigators have sampled S100B from CSF taken from external ventricular drains but, others have been concerned that S100B levels can be altered by ventricular catheter placement; thereby, confounding the speci city of the measurements in brain injury. 19 e majority of the literature reported to date involves the elevation of S100B in patients who have sustained traumatic brain injury. Elevations in this protein have been reported to re ect injury to the brain and increased permeability of the blood brain barrier. eir levels re ect various consequences of severe brain injury such as swelling, contusions, and di use axonal injury. 20 ere are many investigations, which have reported that S100B serum level elevations reliably re ect severe brain injury and that the extent of S100B elevation can reliably predict functional outcomes and even potentially predict patient mortality. ey uniformly have found that serum S100B levels were directly proportional to the severity of injury and inversely proportional to the Glasgow Outcome Score (GOS). Patients with poor outcomes (GOS 1-3) had signi cantly higher serum S100B levels than patients with better outcomes (GOS 4-5) with a P value of < 0.01. Mean S100B levels ranged from 1.1 mcg/l to 4.9 mcg/l in patients with poor outcomes. Patients with better outcomes demonstrated signi cantly lower S100B levels ranging between 0.3 mcg/l and 1.6 mcg/l. Corroborating these results serum S100B levels were found to be elevated more in patients who developed hypotension, hypoxia, or absent pupillary light re exes, which are patients who had a worse outcome. 9, 18, 21 According to Vos et al. 16 the absolute level of S100B elevation during the rst 24 h a er injury might be a reliable predictor of mortality or clinical outcome despite the warnings of others workers. ey reported on a series of 85 patients with severe head injury where the initial S100B levels accurately predicted mortality.
ey found that patients who died had a statistically signi cant higher initial serum S100B level than patients who survived with a P value of < 0.001. e temporal pattern of biochemical markers measured over the ensuing days a er the injury has been studied too. Dimopoulou et al. 22 have reported an investigation of 47 patients with severe brain injury (GCS 3-8 a er neurological resuscitation) where 17 developed the criteria for brain death. All patients underwent serial S100B measurements at the time of admission and every 24h for 6 days. e median S100B level of patients progressing to brain death was 2.32 mcg/l. Survivors had a statistically signi cant lower median S100B level at 1.04 mcg/l (P = 0.0028). According to another study, Raabe et al. 9 showed that secondary increases in S100B levels preceded increased ICP and neuroimaging ndings in patients who subsequently developed secondary brain injury, which culminated in brain death.
So important as a reliable predictor of death and clinical outcome are these studies, which described sustained elevations of S100 in a temporal evaluation.
is might re ect a signi cant original injury or ongoing secondary injury to the brain. ese measurements might a ord us the opportunity to identify patients in the early stages of secondary brain injury. 9, 18 It should be noted that the reliability of S100B as a measure of brain injury depends upon its speci city to brain tissue. ere are many extracranial sources of S100B however muscle and adipose tissue are the most commons. 23 In the clinical context sometimes is difficult to interpret the S100B elevations in patients with brain injury when variable amounts of skeletal muscle injury (polytraumas) can in uence the elevations. e problem of S100B's lack of speci city to brain injury warrants considerations in the evaluation of patients with traumatic brain injury (TBI) and multiple organ lesions. 24, 25 Regarding to this, Savola et al. 26 evaluated the relative contributions of di erent types of head and extracranial traumas on serum S100B levels in 379 consecutive trauma patients. In this series were included 54 patients with cranial and extracranial injuries as well as 155 patients with pure extracranial injuries. ey measured S100B levels within 6 h of injury and then correlated to neurological examinations, injury severity score (ISS) and CT scan ndings. ey found that severe extracranial injuries without brain injury could signi cantly elevate S100B levels. However, the brain injury was associated with signi cantly higher levels of S100B. e median elevation of S100B from head trauma was 0.17 mcg/l while the median elevation of S100B from pure extracranial trauma was signi cantly lower at 0.07 mcg/l (with statistical signi cance). Besides these ndings they con rmed that normal S100B levels were a very reliable predictor of good neurological outcome.
In a similar investigation, Pelinka et al. 23, 24 attempted to determine whether the measurement of S100B serum levels was a reliable marker for TBI in a series of patients with and without multiple organ traumas. All polytraumatized patients demonstrated elevated S100B levels whether or not TBI was present demonstrating that these levels were sensitive to injury outside of the brain too. In the same research the initial S100B levels were highest in non-survivors with TBI and multiple organ injury followed by survivors with TBI and multiple organ injury. erefore, the S100B serum levels taken during the rst 24 h did not reliably predict clinical outcome in this patient population. It was advocated the daily measurement of serum S100B markers as a reliable means of predicting clinical outcome. ey observed that secondary S100B elevations could be used as a reliable marker for the development of secondary brain injury enabling intensivists to initiate clinical interventions at an earlier moment. 25, 27 Translating these results to clinical practice the best mode to di erentiate between the S100B coming from the brain and the body is to look at serial S100B levels over a few days time. e release of S100B from injured skeletal muscle has been found to be short lived and back to normal levels within 20h. Elevations of S100B a er 24 h may more reliably re ect brain injury as long as continued muscle injury is not occurring such as in compartment syndromes. 23, 25, 27 Despite it is not studied yet, the e cacy of interventions could be monitored by following the response of the S100B levels and correlated to clinical outcome studies. It may o er a potential window of opportunity for earlier clinical intervention that may successfully mitigate the clinical impact of secondary brain injury and improve clinical outcomes.
Neuron speci c enolase
NSE is a glycolytic enzyme with a molecular weight of 78 kDa and a biological half-life of 48h. It is functionally active as a heterodimer assembled from alpha, beta and gama subunits. e gama-gama isoform is speci c for neurons, while the alpha-gama isoform is speci c for neuroendocrine cells. is protein is located in the neuronal cytoplasm and is involved in regulating intracellular chloride levels. 15 Others researchers have found that NSE is also present in red blood cells and platelets, decreasing its diagnostic utility as a marker due to possible cross-contamination that could occur in blood samples. [28] [29] [30] Serum levels above 7-10 mcg/L are considered abnormal NSE in serum. e peaks occur within 12 h a er injury and decreases during the subsequent hours. Secondary increases of NSE have been seen in a few patients with poor or fatal outcomes. 10, 31, 32 Statistically signi cant elevation was observed in serum (mean 12.8 mcg/l) and CSF (mean 7.8 mcg/l) levels in patients a er severe traumatic brain injury (n = 51), but only CSF levels showed a correlation with GCS. 33 Vos et al. 16 have demonstrated that serum NSE levels were correlated signi cantly with the injury severity score and CT ndings and were signi cantly higher in nonsurvivors (> 21.7 mcg/l) and in patients with poor outcome 6 months postinjury. Another correlation between temporal serum NSE measurements and GCS and 3-month outcome has also been reported. e secondary increase in the marker was related with a secondary insult such as hypoxia or hypotension; which predicted unfavorable outcome. 34 In clinical studies, serum NSE levels have been frequently studied alongside S-100B. Reports on correlations of serum NSE levels alone with clinical and neurological measures of brain injury magnitude and overall outcome have been controversial although assay of serum NSE together with S100B have been valuable in predicting TBI outcome. 35, 36 ere is a close relationship between the serum NSE levels and GCS score in 2, 24, 48h a er TBI. It is shown that high values of serum NSE a er brain injury are related to poor clinical outcome. Measurement of serum NSE levels may provide useful information about the course of the patients with TBI if it is added to clinical and radiological workups. If these results are con rmed by new large clinic studies, NSE could be used as a helpful screening tool for short-term outcome in TBI. 23 However, like all biomarkers, NSE has limitations. NSE may be limited by the occurrence of false positives with hemolysis and extracranial sources. 25 Some studies suggest that NSE has limited utility as a prognostic index in TBI since its diagnostic utility as a marker due to possible cross-contamination that could occur in blood samples.
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Myelin basic protein
One of the most essential structural proteins in the CNS is the Myelin Basic Protein (MBP), especially in the white matter. It is hypothesized that TBI-mediated axonal injury causes secondary structural damage to the adjacent myelin membrane, resulting in MBP degradation. is potentially could initiate myelin sheath instability and demyelination, which may further promote axonal vulnerability. 38 Normal serum levels of MBP are very low, typically 0.3 ng/ml and high serum MBP levels were found to correlate with worse outcome a er TBI. ese appear to have good specificity but poor sensitivity for TBI. 35 According to Berger et al. in a study involving pediatric TBI patients initial peak MBP concentrations in the serum had a speci city of 96% but sensitivity of only 44%. Children with in icted TBI had later peak concentrations of MBP, similar to that seen with NSE, and higher MPB levels on admission compared to patients with nonin icted TBI. 35, 36 Actually, regarding to this data in these speci c population, the MBP may be useful in predicting outcome a er pediatric TBI. 36 
Glial brillary acidic protein
Serum GFAP might be a useful marker for various types of brain damage in neurodegenerative disorders and in stroke. 39 It is released into the extracellular space in the event of cell damage and is highly speci c to the central nervous system. Such biomarker represents the major part of astroglial cytoskeleton. 40 Animal experiments have demonstrated a time-dependent release of GFAP a er severe cortical impact injury in rats. In these cases the highest levels were observed 1-hour a er the trauma. 10 According to Missler et al. 40 pathological levels are those higher than 0.033 mcg/l. Human studies shows that the highest levels of GFAP are observed in the rst days a er de TBI. ere are studies correlating this biomarker with Marshall Classi cation of Cerebral CT scan. e GFAP was lower in Di use Injury II (cisterns present with midline shi of 0-0.5 cm and/ or no focal lesion of > 25 ml) than in Di use Injury IV (swelling, midline shi of > 0.5 cm, no lesion of > 25 ml). Additionally, GFAP was lower in Di use Injury II than in nonevacuated mass lesions. It should be noted that GFAP levels are normal in polytrauma patients without TBI.
25 Discussion e present review shows that there has been an increasing interest in biochemical markers for traumatic brain injury during the last years. e potential correlation of markers with injury and outcome measures in severe head injury is promising. e S-100B protein has been intensively investigated in severe head injury. Several papers found signi cant correlation unanimously between the marker and both the injury and the outcome. erefore, multicenter investigation and the introduction of S-100B into the clinical routine should be considered with caution since the multiple organ traumas can also contribute to the higher serum levels.
Regarding to the others biomarkers (GFAP, NSE and MBP), there are few studies, however they also show promising results.
It should be emphasized that the aim to nd an ideal biomarker has proved di cult for several reasons. e brain is a hugely complex organ and is protected by a selective blood brain barrier. Its functions are both qualitative and quantitative, while most biomarkers are purely quantitative. For example, lobar injury has di erent consequences for outcome compared with the same volume of tissue injury in the brainstem. Furthermore, extracranial sources of the biomarker also may limit its speci city. e level of a biomarker in the serum may also re ect both the degree of cellular injury and/or the degree of blood brain barrier disruption. Finally, as in most aspects of TBI, there are many clinical variables and physiopathological factors that a ect the patient outcome.
Conclusion
Several biomarkers of brain injury have been identi ed and continued research is required. In the future it may be possible to nd biomarkers that accurately predict the temporal evolution of secondary damage or biomarkers that provide assistance in the establishment of diagnosis and outcome. Probably a single biomarker will not be able to accurately predict which patients are at risk for speci c outcomes. Future studies will be necessary to develop a useful test in which a panel of TBI-associated biomarkers are evaluated and used to prompt treatment.
